Horizon Kinetics Medical ETF Rating → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free MEDX Stock Alerts $28.30 -0.36 (-1.26%) (As of 05/28/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHoldingsRatingsTrendsStock AnalysisChartDividendHoldingsRatingsTrends Horizon Kinetics Medical ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.MEDX Aggregate RatingModerate Buy2.60Holdings in MEDX have an aggregate rating of Moderate Buy based on 345 analyst ratings issued in the past year covering 32 companies (88.6% of the portfolio).MEDX Aggregate Price Target$38.3135.38% UpsideHigh Prediction$50.71Average Prediction$38.31Low Prediction$26.58Holdings in MEDX have an aggregate price target of $38.31 and a range of $26.58 to $50.71 covering 32 companies (88.6% of the portfolio).MEDX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Horizon Kinetics Medical ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 32 MEDX Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings15.17%LLYEli Lilly and Company$807.86+0.1%5 of 5 stars2.84$769.53 -4.7%19Insider Selling7.21%ABBVAbbVie$155.37-1.1%5 of 5 stars2.79$176.14 13.4%14Short Interest ↑6.15%AMGNAmgen$300.19-1.8%5 of 5 stars2.52$305.65 1.8%21Short Interest ↑Analyst Revision5.67%AZNAstraZeneca$76.62-2.4%2 of 5 stars2.57$82.00 7.0%7Short Interest ↓5.12%MRKMerck & Co., Inc.$126.11-2.6%4 of 5 stars2.58$131.33 4.1%12News CoveragePositive News5.05%JNJJohnson & Johnson$144.40-1.7%5 of 5 stars2.46$175.86 21.8%134.65%BMYBristol-Myers Squibb$40.49-1.8%5 of 5 stars2.11$60.00 48.2%19Analyst Revision4.27%PFEPfizer$28.32-1.9%5 of 5 stars2.40$35.86 26.6%154.08%REGNRegeneron Pharmaceuticals$973.16-1.2%4 of 5 stars2.76$989.36 1.7%214.07%BIIBBiogen$218.73+0.4%5 of 5 stars2.65$288.46 31.9%26Short Interest ↑3.31%CRSPCRISPR Therapeutics$54.84-0.7%2 of 5 stars2.35$73.57 34.2%17Short Interest ↑3.27%ALKSAlkermes$23.75-1.1%5 of 5 stars2.50$36.78 54.9%10Analyst Revision2.95%GSKGSK$44.25-2.0%2 of 5 stars2.405Short Interest ↑2.88%IONSIonis Pharmaceuticals$37.64+1.0%4 of 5 stars2.71$59.54 58.2%14Positive News2.55%ALNYAlnylam Pharmaceuticals$150.06+1.6%5 of 5 stars2.59$216.19 44.1%17Positive News2.09%NTLAIntellia Therapeutics$22.72-8.5%4 of 5 stars2.69$66.77 193.9%13Positive News1.99%BCYCBicycle Therapeutics$22.98-0.2%1 of 5 stars2.86$46.86 103.9%71.27%BEAMBeam Therapeutics$24.22-0.4%1 of 5 stars2.38$40.18 65.9%13Positive News1.15%LTRNLantern Pharma$6.18-1.4%0 of 5 stars2.001News CoveragePositive News1.03%EDITEditas Medicine$5.32-5.5%4 of 5 stars2.50$13.90 161.3%101.02%GALTGalectin Therapeutics$2.82-7.5%1 of 5 stars3.00$11.00 290.1%1Short Interest ↑Negative News0.68%HLNHaleon$8.40+0.2%3 of 5 stars2.754Short Interest ↓0.57%REPLReplimune Group$5.18-0.8%4 of 5 stars3.00$37.67 627.2%30.46%GEHCGE HealthCare Technologies$78.75-1.4%4 of 5 stars2.60$94.80 20.4%10Short Interest ↓Positive News0.45%TSVT2seventy bio$4.27-5.3%3 of 5 stars2.60$12.86 201.1%100.39%SDZNYSandoz Group$35.45+1.3%2 of 5 stars3.0030.32%ALLOAllogene Therapeutics$2.43-3.6%3 of 5 stars2.67$9.80 303.3%9Short Interest ↑0.24%BLUEbluebird bio$0.94-3.1%2 of 5 stars2.27$5.74 511.0%11Gap Up0.23%VTRSViatris$10.39-0.2%1 of 5 stars1.33$11.00 5.9%3Insider Selling0.12%PACBPacific Biosciences of California$1.883 of 5 stars2.53$6.59 251.5%150.09%SLRXSalarius Pharmaceuticals$0.46-4.1%1 of 5 stars2.001Short Interest ↓Positive NewsGap Down0.05%MURAMural Oncology$3.58-0.3%2 of 5 stars3.00$13.00 263.1%1Short Interest ↓ This page (NASDAQ:MEDX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestThe #1 Crypto for AIWeiss RatingsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Kinetics Medical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
